Canada markets open in 7 hours 12 minutes

IMV Inc. (IMV.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.7400-0.1200 (-4.20%)
At close: 03:59PM EST
Full screen
Previous Close2.8600
Open2.8400
Bid2.7300 x 0
Ask2.7700 x 0
Day's Range2.7000 - 2.8600
52 Week Range2.7000 - 19.3000
Volume36,801
Avg. Volume21,828
Market Cap32.018M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.6690
Earnings DateMar 14, 2023 - Mar 20, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.74
  • Business Wire

    IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

    DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., January 08, 2023--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).

  • Business Wire

    IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 20, 2022--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today the closing of its previously announced registered direct offering (the "Offering") for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each,

  • Business Wire

    IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 16, 2022--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today that it has entered into definitive agreements for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each, a "Share" and, collectively, the "Sha